You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 HIV and Hepatitis.com Coverage of the
18th Conference on Retroviruses and
Opportunistic
Infections (CROI 2011)
 February 27 - March 2, 2011, Boston, MA
  The material posted on HIV and Hepatitis.com about CROI 2011 is not approved by nor is it a part of CROI 2011.
Library of Slides and Posters
HIV/AIDS Articles
HIV/HCV and HIV/HBV Coinfection Articles


    Google Custom Search
HIV/AIDS Articles
Can Lowering Community Viral Load Decrease New HIV Infections?
Noimage
HPV and Anal Cancer Research at CROI 2011
HIV Enters and Injures Brain Early
Vitamin D May Reduce Tenofovir-related Bone Loss
Do Black Patients Respond Less Well to Antiretroviral Therapy?
Immediate ART Improves Survival for HIV+ People with TB
Reduced Limb Muscle, More Belly Fat Linked to Higher Mortality
Studies Shed Further Light on Cardiovascular Disease among People with HIV
Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
Longer Preventive Therapy, More Drugs Reduce Risk of Mother-to-Child HIV Transmission
Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV
Is Bone Loss Related to Immune Reconstitution in People on ART?
New Tenofovir Pro-drug GS-7340 Looks Good in Early Study
5 Drugs No Better than 3 for Treatment of Primary HIV Infection
Long-term Benefits of Circumcision for HIV Prevention
No More Science Fiction -- HIV Gene Therapy Delivers
Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing
HIV Attachment Inhibitor BMS-663068 Shows Good Activity in Phase 2a Trial
Researchers Report Further Findings from iPrEx PrEP Trial
Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
FDA Safety Review Does Not Find Abacavir-Heart Attack Link
International AIDS Society Launches International HIV Cure Working Group
HIV/HCV and HIV/HBV Coinfection Articles
HCV Re-infection Common among HIV+ Gay Men in Amsterdam
HIV/HCV Coinfected People Have Higher Risk of Bone Loss
Acute Hepatitis C Treatment for HIV/HCV Coinfected People
Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
Liver Fibrosis Raises Risk of Kidney Impairment in HIV/HBV Coinfected Patients on Tenofovir
Little Overlap of Sexually Transmitted HCV between U.S. and Europe
More Liver-related Death for HIV/HBV than HIV/HCV Coinfection in MACS Cohort
Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People
Library of Slides and Posters
Success of Test and Treat in San Francisco? Reduced Time to VirologicSuppression, Decreased Community Viral Load, and Fewer New HIV Infections, 2004 to 2009
M Das and others. CROI 2011.
Use of Community Viral Load as Population-Based Biomarker of HIV „Ÿ Washington, DC, 2004 . 2008
A Castel and others. CROI 2011.
Disparities in Community Viral Load among HIV Infected Persons in NYC
F Laraque and others. CROI 2011.
HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors
M Freiberg and others. CROI 2011.
Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members
D Klein and others. CROI 2011.
No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis
X Ding and others. CROI 2011.
Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years Treatment (Tx): 156 Week (Wk) Results from STARTMRK
J Rockstroh and others. CROI 2011.
ARIEL: 24-week safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years
A Violari and others. CROI 2011.
Pharmacokinetic Parameters of Once-Daily TMC278 Following Administration of Efavirenz in Healthy Volunteers
H Crauwels and others. CROI 2011.
Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 data from the randomized, double-blind, Phase III ECHO and THRIVE trials
J Arribas and others. CROI 2011.
Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
A Mills and others. CROI 2011.
Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial
D Wohl and others. CROI 2011.
GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir DisoproxilFumarateDuring 14 Days of Monotherapyin HIV-1 Infected Subjects
A Diamond and others. CROI 2011.
No Association of Myocardial Infarction with ABC Use: An FDA Meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections
X Ding and others. CROI 2011.

 

CROI 2011 News